AngioDynamics Partners with UCLH for Prostate Cancer Research
AngioDynamics, Inc. (NASDAQ: ANGO), a prominent medical technology firm, has embarked on an ambitious international multi-center study aimed at exploring the long-term outcomes of the NanoKnife System in treating unifocal intermediate-risk prostate cancer. This initiative is in collaboration with University College London Hospital (UCLH), known for its pioneering work in the fields of focal therapy and surgical treatments for prostate cancer.
Understanding the Impact of Intermediate-Risk Prostate Cancer
Prostate cancer represents a significant health challenge, with approximately 40% of diagnosed cases categorized as intermediate risk. Patients often face severe side effects post-treatment, making innovative solutions imperative. Traditional treatments such as radical surgery have been reported to lead to urinary leakage in 36% of patients and a staggering 95% of men experience some form of erectile dysfunction, with 70% indicating moderate to severe conditions.
Revolutionary Treatment: The NanoKnife System
The NanoKnife System has emerged as a groundbreaking option, circumventing the complications often associated with conventional therapies. By utilizing a non-thermal methodology, it aims to preserve vital structures surrounding the prostate while effectively targeting tumors. Its design supports lower complication rates and prioritizes minimal disruption to quality of life for the patient.
Moving Toward Widespread Acceptance
In a notable advancement, the National Institute for Health and Care Excellence (NICE) in the U.K. recently elevated the NanoKnife System's status from "Research Only" to "Special Arrangements". This change signifies broader acceptance in the medical community and allows hospitals to introduce this innovative treatment while collecting data to further assess its effectiveness.
A Collaborative Effort for Better Patient Outcomes
The collaboration between AngioDynamics and UCLH reflects a commitment to pushing the boundaries of treatment for prostate cancer. UCLH, recognized as the largest center for robotic prostate surgery in the U.K., has become a forerunner in employing the NanoKnife System. The facility serves as a model for standardized patient selection and long-term follow-up care.
Insights from the Leadership
Laura Piccinini, Senior Vice President and General Manager of Endovascular Therapies at AngioDynamics, commented on the significance of correcting patient treatment pathways through this extensive study. She highlighted that the aim is not just to present data, but to genuinely contribute to the improvement of treatments accessible for men with prostate cancer throughout the U.K.
Professor Mark Emberton from UCLH echoed this sentiment by stressing the importance of long-term data collection. He stated that this international registry will allow for regular evaluation of patient outcomes and enhance the quality control of the technology’s application worldwide.
Study Design and Future Prospects
Enrolment for this groundbreaking study will include a minimum of 500 patients globally. Previous research indicates the NanoKnife System is both safe and effective for targeted tumor treatment while safeguarding patient quality of life. The study will complement existing randomized controlled trials comparing NanoKnife with traditional radical treatments, illustrating a comprehensive approach to evaluating this novel therapy.
Tracking outcomes related to patient quality of life, overall survival, and disease-specific mortality will be pivotal components of the study, ultimately aiming to establish the NanoKnife System as a standard treatment option.
Conclusively Improving Cancer Treatment
With a focus on patient care, AngioDynamics continues to innovate within the medical technology sector, providing new avenues for addressing unmet clinical needs. The company is dedicated to improving the quality of life for patients diagnosed with intermediate-risk prostate cancer, ensuring that groundbreaking treatments such as the NanoKnife System can be widely adopted and integrated into everyday practice.
About AngioDynamics, Inc.
AngioDynamics is renowned for its role in enhancing healthcare through innovative medical technology solutions. Committed to advancing patient treatment options, the company strives to work closely with healthcare providers to address complex clinical challenges.
Frequently Asked Questions
What is the purpose of the study involving the NanoKnife System?
The study aims to assess the long-term effects of the NanoKnife System in treating men with unifocal intermediate-risk prostate cancer.
Who is conducting this international study?
AngioDynamics, Inc. is leading the study in partnership with University College London Hospital (UCLH).
What are the expected outcomes for participants in this study?
Participants can expect to contribute to significant data collection that may help refine treatment methods and support broader access to innovative therapies.
How many patients will be enrolled in the study?
A minimum of 500 patients will be enrolled worldwide to ensure comprehensive findings.
What does the NanoKnife System offer compared to traditional treatments?
The NanoKnife System provides a non-thermal treatment option that aims to minimize complications related to urinary and sexual functions, improving quality of life for patients.
